Abstract 207P
Background
Diabetes mellitus is considered as a potential risk factor for breast cancer, yet the relationship between diabetic background retinopathy (DBR) and breast cancer remains uncertain. This study leverages mendelian randomization (MR) to explore the genetic link between diabetic background retinopathy (DBR) and estrogen receptor-positive (ER+) breast cancer, highlighting the connection with diabetes-related conditions.
Methods
We acquired summary data from a genome-wide association study (GWAS) concerning DBR in the European population, with a focus on their relationship with ER+ breast cancer. We performed two-sample MR analysis with multiple approaches to evaluate the potential causal associations between DBR and ER+ breast cancer. Pleiotropy and Cochran's Q tests were utilized to determine horizontal pleiotropy and heterogeneity.
Results
Of the 205,044 participants (2,026 DBR cases) from FinnGenn, we identified 8 single nucleotide polymorphisms (SNPs) associated with the risk of ER+ breast cancer (69,501 ER+ breast cancer cases from iCOGS). The MR analysis showed a suggestive association between DBR susceptibility and ER+ breast cancer (weight median odds ratio [OR]: 0.971, 95% confidence interval [CI]: 0.955-0.987, P = 0.0006; simple mode OR: 0.964, P = 0.043; weight mode OR: 0.971, P = 0.015). The effect size estimate (β) for weight median model was -0.0294, indicating a 2.94% decrease in the odds of ER+ breast cancer per unit increase in genetically predicted DBR. Sensitivity analyses are consistent with the results, manifesting that our findings were convincing and robust.
Conclusions
These finding suggests that a potential inverse relationship between DBR and the risk of ER+ breast cancer. These findings could significantly impact screening and prevention strategies for diabetic populations, emphasizing the need for further research into this association.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1173P - Combining mass spectrometry with quantitative continuous scoring to unlock the full quantitative potential of immunohistochemistry
Presenter: Ana Hidalgo-Sastre
Session: Poster session 09
1174P - FLAMINGO: Accurate cancer detection from ultra-low-pass whole genome sequencing of cell-free DNA
Presenter: Daan Vessies
Session: Poster session 09
1175P - Universal circulating tumor DNA quantification using deep learning
Presenter: Anders Skanderup
Session: Poster session 09
Resources:
Abstract
1176P - Potential utility of ctDNA to detect false positive PET/CT in the evaluation of lymphoma response
Presenter: Alejandro martín-muñoz
Session: Poster session 09
1177P - FRESH: The Gustave Roussy program to facilitate access to liquid biopsy for precision oncology in France
Presenter: Etienne Rouleau
Session: Poster session 09
1178P - EGFR evaluation in non-small cell lung cancer: An artificial intelligence approach to pre-molecular analysis
Presenter: Chad Vanderbilt
Session: Poster session 09
1179P - WomEC: a novel diagnostic test for the detection of endometrial cancer in uterine fluids
Presenter: Antonio Gil-Moreno
Session: Poster session 09
1180P - An integrated metabolomics-based platform for early-stage detection of multiple cancers
Presenter: imliwati longkumer
Session: Poster session 09
1181P - Diagnostic target product profiles for cancer: A demand signaling tool to stimulate innovation in early cancer diagnosis
Presenter: Sonja Marjanovic
Session: Poster session 09